Variability in response to clozapine: Potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene

CNS Spectrums

Volumn 4, Issue 6, 1999, Pages 30-56

  Ozdemir, Vural ^a   Masellis, Mario ^a   Basile, Vincenzo S ^a   Kalow, Werner ^a   Meltzer, Herbert Y ^a   Lieberman, Jeffrey A ^a   Kennedy, James L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; PHENACETIN O DEETHYLASE;

AGRANULOCYTOSIS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HUMAN; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

EID: 0033022950     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s109285290001186x     Document Type: Review

References (127)

1. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry. 1998;59(suppl 3):38-43.
2. Kane JM. Schizophrenia. W Engl J Med. 19%;334: 34-41.
3. Lieberman JA. Atypical antipsychotie drugs as a firstline treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 19%;57(suppl 11):68-71.
4. Meltzer H Y. Atypica] antipsychotie drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1277-1286.
5. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinel. 1993;24:161-176.
6. Collins EJ, Lalonde P, Jones BD, et al. Clozapine in the treatment of refractory schizophrenia: Canadian policfes and clinical guidelines. Can J Psychiatry. 1992;37:482-496.
7. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotie agent. N Engl J Med. 1991;324:746-754.
8. Miller DD. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry. 1996;8:99-109.
9. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry. 1994;55(suppl B):161-165.
10. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275-291.
11. Sheiner LB. Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther. 1989;46:605-615.
12. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev. 1997;49:369-379.
13. Llerena A, Cobaleda J, Martinez C, Benitez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet. 1996;21:129-138.
14. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29:192-209.
15. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen. 1995;25(suppl26):102-114.
16. Llerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther. 1993;54:606-611.
17. Reidenberg MM. Trends in clinical pharmacokinetics. Clin Pharmacokinet. 1993;24:l-9.
18. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther. 1990;45:241-298.
19. Creenblatt DJ, Harmatz JS, von Moltke LL, Shader RI. Pharmacokinetics and pharmacodynamics. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:849-858.
20. Rowland M, Tozer TN, eds. Clinical Pharmacokinetics. Concepts and Applications. 3rd ed. Philadelphia, Pa: Williams & Wilkins; 1995.
21. Sindrup SH, Brisen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995;5:335-346.
22. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346-352.
23. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. 1. Evidence for its hemoprotein nature. JBiolChem. 1964;39:2370-2378.
24. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. 2. Solubilization, purification, and properties. J Biol Chem. 1964;239:2379-2385.
25. Guengerich FP. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett. 1994;70:133-138.
26. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:l-42.
27. Neben DW, Adesnik M, Coon MJ, et al. The P450 gene superfamily. Recommended nomenclature. DNA. 1987;6:1-11.
28. Nebert DW, Nelson DR, Adesnik M, el al. The P450 gene superfamily. Update on the naming of new genes and nomenclature of chromosomal loci. DNA. 1989;8: 1-13.
29. Nebert DW, Nelson DR, Coon MJ, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991;IO: 1-14.
30. Nelson DR, Kamataki T, Waxman DJ, el al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol. 1993;12:1-51.
31. Sl.Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414423.
32. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in thé United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry. 1994;(suppl B):78-81.
33. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:93-100.
34. Compendium of Pharmaceuticals and Specialties. Clozaril Monograph. Canadian Pharmacists Association; Ottawa, Ontario; 1994:262-264.
35. Cheng YF, Lundberg T, Bondesson U, Lindstrom L, Gabrielsson J. Clinical pharmacokinelics of clozapine in chronic schizophrenic patients. EUT J Clin Pharmacol. 1988;34:445-449.
36. Choc MG, Hsuan F, Honigfeld G, et al. Single- vs multiple-dose phamiacokinetics of clozapine in psychiatrie patients. Pharm Res. 1990;7:347-351.
37. Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 1987;4:402405.
38. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55(suppl B):133-136.
39. Ozdemir V, Posner P, Collins EJ, et al. CYP1A2 activity predicts clozapine steady state concentration in schizophrenic patients [abstract]. Clin Pharmacol Ther. 1999;65:175.
40. Carrillo JA, Herraiz AC, Ramos SI, Benftez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18:311-316. 41.Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol. 19%;16:177-187.
41. Dain JG, Nicoletti J, Ballard F. Biotransformation of clozapine in humans. Drug Metab Dispos. 1997;25: 603-609.
42. Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993;245:179-182.
43. Young CD, Meltzer HY, Deutch AY. Effects of desmethylclozapine on Eos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacology. 1998;19:99-103.
44. Chang WH, Lin SK, Lane HY, et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropychopharmacol Biol Psychiatry. 1998;22:723-739.
45. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Ada Drug Res. 1994;25:l-53.
46. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991;12:102-107.
47. Un K-M, Poland RE, Wan Y-JY, Smith MW, Lesser IM. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull. 1996;32:205-217.
48. Lin K-M, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asians and Caucasian schizophrenic patients. Am J Psychiatry. 1989;146:1307-1311.
49. Lin K-M, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol. 1988;8:195-201.
50. Chong SA, Tan CH, Khoo YM, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit. 1997;19:219-223.
51. Matsuda KT, Clio MC, Lin KM, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull. 1996;32:253-257.
52. Lin KM, Andersen D, Poland RE. Ethnicity and psy-chopharmacology: bridging the gap. Psychiatr Clin North Am. 1995;18:635-647.
53. SI. Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 1998;32:567-574.
54. VanderZwaag C, McGee M, McEvoy JP, Freudenreich 0, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153:1579-1584.
55. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatmentrefractory schizophrenic patients. Am J Psychiatry. 1995;152:179-182.
56. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55(supplB):117-121.
57. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry. 1994;55(suppl B):94-97.
58. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;13:383-390.
59. Perry P, Miller D, Amdt S, Cadoret R. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. Am J Psychiatry. 1991;148:231-235.
60. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry. 1995;152:821-825.
61. Fang J, Coutts RT, McKenna KF, Baker GB. Elucidation of individual P cytochrome 450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedeberg's Arch Pharmacol. 1998;358:592-599.
62. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439-446.
63. Linnet K, Olesen 0V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos. 1997;25:1379-1382.
64. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272:984-990.
65. Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther. 1992;260:1355-1360.
66. Shader RI, Greenblatt DJ. Clozapine and fluvoxamine, a curious complexity. J Clin Psychopharmacol. 1998;18:101-102.
67. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation of clozapine by flavincontaining monooxygenase. Drug Metab Dispos. 1997;25:524-527.
68. Kalow W, Tang BK. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effects of cigarette smoking. Clin Pharmacol Ther. 1991;49:44-48.
69. Schmider J, Greenblatt DJ, von Moltke LL, Shader RL Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol. 19%;16:267-272.
70. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries witli CYP1A2 activity determined by a caffeine test. 1994. Br J Clin Pharmacol. 1994;38: 471-473.
71. Kashuba AD, Nafziger AN, Keams GL, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998;64:257-268.
72. Rasmussen BB, Nielsen TL, Br0sen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83:240-245.
73. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinel. 1997;32(suppl 1):1-21.
74. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol. i998;18:2-9.
75. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage [letter]. J Clin Psychiatry. 1997;58:499.
76. Taylor D. Pharmacokinetic interactions involving clozapine. ET J Psychiatry. 1997;171:109-112.
77. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 1994;14:279-281.
78. Jerling M, Lindstrom L, Bondesson U, Bertilsson L Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-374.
79. Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry. 1998;55:1048-1050.
80. Dahl ML, Llerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol. 1994:37:71-74.
81. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995;39:417-420.
82. Raaska K, N'euvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 1998;54:167-170.
83. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med. 1996;156:675-677.
84. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8.-283-289.
85. Tang BK, Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol. 1996;272:124-131.
86. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics. 1994;4:117-124.
87. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53:503-514.
88. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991:50:508-519.
89. Kashuba AD, Bertino JS Jr, Kearns GL, et al. Quantitäten of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acelyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther. 1998;63:540-551.
90. Kail MA, Vang 0, Clausen J. Effects of dietary broccoli on human drug metabolising activity. Cancer Lett. 1997;114:169-170.
91. Kail MA, Vang 0, Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis. 1996;17:793-9.
92. Sinha R, Rolhman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res. 1994;S1:6154-6159.
93. Fuhr U, Klitticli K, Staib AH. Inhibitor)' effect of grapefruit juice and the active component naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35:431-436.
94. Masimirembwa CM, Beke M, Hasler JA, Tang BK, Kalow W. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther. 1995;57:25-31.
95. 96.0'Connell MB, Frye R, Peter JV. Effect of conjugated estrogen replacement therapy on GYP activity. Clin Pharmacol Ther. 1997;61:226.
96. Sarich T, Kalhorn T, Magee S, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62:21-28.
97. Rost KL, Brosicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology. 1994;20:1204-1212.
98. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992;51:388-397.
99. Jurima M, Inaba T, Kadar D, Kalow \K Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985;19:483-487.
100. Nakamura K, Goto F, Ray WA, et al. Interelhnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38:402-408.
101. Ashby CR, Wang RY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. .Synapse. 1996;24:349-394.
102. Farde L, N'ordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central Dl and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
103. N'ordstrom AL, Farde L, iN'yberg S, Karlsson P, Halldin C, Sedvall G. Dl, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-1449.
104. Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature. 1974;248:596-597.
105. Snyder SH, Greenberg D, Yamumura HI. Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J Psychiatr Res. 1974;11: 91-95.
106. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Bed). 1996;124:2-34.
107. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exper Ther. 1989;251:238-246.
108. Meltzer HY, Fatemi SH. The role of serotonin in schizophrenia and the mechanism of action of anti-psychotic drugs. In: Kane JM, Möller H-J, Awouters F, eds. Serotonergic Mechanisms in Antipsychotic Treatment. New York, NY: Marcel Dekker, 1996:77-107.
109. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55(suppl B):47-52.
110. Van Toi HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991;350:610-614.
111. Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 1992;7:261-284.
112. Seeman P, Van Toi HHM. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. EUT J Pharmacol. 1995;291:59-66.
113. Sanyal S, Van Toi HHM. Review. The role of dopamine D4 receptors in schizophrenia and antipsychotic action.} Psychiatr Res. 1997;31:219-232.
114. Paterson AD, Sunohara GA, Kennedy JL. Dopamine D4 receptor gene: novelty or nonsense? Neuwpsychopharmacology. In press.
115. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine [letter]. Lancet. 1993;341:116.
116. Shaikh S, Collier DA, Sham P, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet. 1995;60:S41-545.
117. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 1994;51:912-917.
118. Badri F, Masellis M, Petronis A, et al. Genetic studies of dopamine and serotonin system genes in clinical response to clozapine [abstract]. Am J Hum Genet. 1996;57:1358..
119. Rietschel M, Naber D, Oberlander H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology. 1996;15(5):491-496.
120. Kohn Y, Ebstein RP, Heresco Levy U, et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. EUT Neuropsychopharmacol. 1997;7:39-43.
121. Hebebrand J, Nothen MM, Ziegler A, et al. Nonreplication of linkage disequilibrium between the dopamine D4 receptor locus and Tourelle syndrome [letler]. Am J Hum Genet. 1997;61:238-239.
122. LaHoste GJ, Swanson JM, Wigal SB, el al. Dopamine D-l receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1996;1:121-124.
123. Swanson JM, Sunohara GA, Kennedy JL, et al. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry. 1998;3:38-41.
124. Sunohara GA, Kennedy JL. The dopamine D4 receptor gene and neuropsychiatrie disorders. In: Savage LM, ed. Dopaminergic Disorders: Novel Approaches for Drug Discovery and Development. IBC Library Series. Southborough, Mass: IBC;1998:29-42.
125. Masellis M, Basile V, Meltzer HY, et al. Serolonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19:123-132.
126. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998;32:93-99.
127. Rietschel M, Kennedy JL, Macciardi FM, DeLisi L, Meltzer HY, and the Consensus Group for Outcome Measures in Psychoses for Pharmacogenetic Studies. Pharmacogenetics in psychosis: the first consensus conference. Schizophr Res. In press.